J&J Leans Toward DePuy Synthes Spinoff, Targets Mid-2027
Johnson & Johnson ($JNJ) is leaning toward spinning off DePuy Synthes, its orthopaedics business, rather than pursuing a sale. In prepared remarks accompanying its October 13 earnings release, CFO Joseph Wolk said a spinoff currently looks like the best way to create long-term shareholder value. J&J continues to evaluate other structures and expects the separation by mid-2027. A… Read More »